163 related articles for article (PubMed ID: 28961308)
21. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
[TBL] [Abstract][Full Text] [Related]
22. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions.
Miller LH; Maxa KL; Winter SS; Gossai NP
Expert Rev Anticancer Ther; 2023; 23(12):1229-1236. PubMed ID: 37850259
[TBL] [Abstract][Full Text] [Related]
23. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
DeAngelo DJ
Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
[TBL] [Abstract][Full Text] [Related]
24. MR imaging in nelarabine-induced myelopathy.
Dua SG; Jhaveri MD
J Clin Neurosci; 2016 Jul; 29():205-6. PubMed ID: 26899359
[TBL] [Abstract][Full Text] [Related]
25. Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma.
Luskin MR; Ganetsky A; Landsburg DJ; Loren AW; Porter DL; Nasta SD; Svoboda J; Luger SM; Frey NV
Br J Haematol; 2016 Jul; 174(2):332-4. PubMed ID: 26403537
[No Abstract] [Full Text] [Related]
26. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival.
Forcade E; Leguay T; Vey N; Baruchel A; Delaunay J; Robin M; Socié G; Dombret H; Peffault de Latour R; Raffoux E
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1124-6. PubMed ID: 23648236
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL.
Horibe K; Takimoto T; Yokozawa T; Makimoto A; Kobayashi Y; Ogawa C; Ohno R; Koh N; Katsura K; Tobinai K
Rinsho Ketsueki; 2011 Jun; 52(6):406-15. PubMed ID: 21737993
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
Kathpalia M; Mishra P; Bajpai R; Bhurani D; Agarwal N
Ann Hematol; 2022 Aug; 101(8):1655-1666. PubMed ID: 35727338
[TBL] [Abstract][Full Text] [Related]
29. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
Gökbuget N; Basara N; Baurmann H; Beck J; Brüggemann M; Diedrich H; Güldenzoph B; Hartung G; Horst HA; Hüttmann A; Kobbe G; Naumann R; Ratei R; Reichle A; Serve H; Stelljes M; Viardot A; Wattad M; Hoelzer D
Blood; 2011 Sep; 118(13):3504-11. PubMed ID: 21715318
[TBL] [Abstract][Full Text] [Related]
30. Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient.
Papayannidis C; Iacobucci I; Abbenante MC; Curti A; Paolini S; Parisi S; Baccarani M; Martinelli G
Am J Hematol; 2010 Aug; 85(8):608. PubMed ID: 20658590
[No Abstract] [Full Text] [Related]
31. Nelarabine-induced myelopathy in patients undergoing allogeneic hematopoietic cell transplantation: a report of three cases.
Fukuta T; Tanaka T; Hashimoto T; Isahaya K; Kubo Y; Yamano Y; Satomi K; Hiraoka N; Shirakawa N; Arakawa A; Ogawa C; Nishimura N; Aoki J; Ito A; Inamoto Y; Kim SW; Fukuda T
Int J Hematol; 2023 Jun; 117(6):933-940. PubMed ID: 36705847
[TBL] [Abstract][Full Text] [Related]
32. Coma associated with nelarabine in an elderly patient with T-cell acute lymphoblastic leukemia and severe chronic renal disease.
Nishijima TF; Shea TC; Wood WA; Voorhees PM; Jamieson K
Leuk Lymphoma; 2016; 57(4):957-60. PubMed ID: 26293208
[No Abstract] [Full Text] [Related]
33. Clofarabine and nelarabine: two new purine nucleoside analogs.
Gandhi V; Plunkett W
Curr Opin Oncol; 2006 Nov; 18(6):584-90. PubMed ID: 16988579
[TBL] [Abstract][Full Text] [Related]
34. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.
Kadia TM; Gandhi V
Expert Rev Hematol; 2017 Jan; 10(1):1-8. PubMed ID: 27869523
[TBL] [Abstract][Full Text] [Related]
35. [Severe liver injury following nelarabine chemotherapy for T-cell lymphoblastic lymphoma].
Iino M
Rinsho Ketsueki; 2009 Jan; 50(1):49-51. PubMed ID: 19225230
[TBL] [Abstract][Full Text] [Related]
36. Irreversible neurological defects in the lower extremities after haploidentical stem cell transplantation: possible association with nelarabine.
Kawakami M; Taniguchi K; Yoshihara S; Ishii S; Kaida K; Ikegame K; Okada M; Watanabe S; Nishina T; Hamada H; Nakagawa M; Ogawa H
Am J Hematol; 2013 Oct; 88(10):853-7. PubMed ID: 23757212
[TBL] [Abstract][Full Text] [Related]
37. Nelarabine toxicity in children and adolescents with relapsed/refractory T-ALL/T-LBL: can we avoid throwing the baby out with the bathwater?
Malone A; Smith OP
Br J Haematol; 2017 Oct; 179(2):179-181. PubMed ID: 28891074
[No Abstract] [Full Text] [Related]
38. Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed.
Prescrire Int; 2009 Feb; 18(99):3-5. PubMed ID: 19382393
[TBL] [Abstract][Full Text] [Related]
39. Nelarabine: efficacy in the treatment of clinical malignancies.
Roecker AM; Allison JC; Kisor DF
Future Oncol; 2006 Aug; 2(4):441-8. PubMed ID: 16922610
[TBL] [Abstract][Full Text] [Related]
40. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
Shimony S; DeAngelo DJ; Luskin MR
Blood Adv; 2024 Jan; 8(1):23-36. PubMed ID: 37389830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]